Christopher A. Pargellis

Author

Boehringer Ingelheim (United States)

Also Known As

C A Pargellis, C.A. Pargellis, Christopher A. Pargellis

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (United States)Boehringer Ingelheim (France)Boehringer Ingelheim (Japan)Boehringer Ingelheim (Spain)Brown University

About

Christopher A. Pargellis is an author at Boehringer Ingelheim (United States) specializing in medicine, natural sciences, and chemical biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	772
2	Natural Sciences	8	8	620
3	Biochemistry	6	6	220
4	Cell Biology	3	3	465
5	Cellular Physiology	1	1	386

Christopher A. Pargellis

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket Liang Tong, Susan Pav, Della White, Nature Structural Biology Specific InhibitorSignal TransductionSignaling PathwayMolecular PathwayNatural Sciences	1997	386
Suicide recombination substrates yield covalent lambda integrase-DNA complexes and lead to identification of the active site tyrosine. Christopher A. Pargellis, Simone E. Nunes-Düby, Lina Moitoso de Vargas, Journal of Biological Chemistry	1988	190
Autonomous DNA binding domains of λ integrase recognize two different sequence families Lina Moitoso de Vargas, Christopher A. Pargellis, Noaman Hasan, Cell Different Sequence FamiliesSequence MotifDna SequencingGeneticsλ Integrase	1988	148
The kinetics of binding to p38 MAP kinase by analogues of BIRB 796 John R. Regan, Christopher A. Pargellis, Pier F. Cirillo, Bioorganic & Medicinal Chemistry Letters	2003	111
Molecular basis of MAPK-activated protein kinase 2:p38 assembly André White, Christopher A. Pargellis, Joey Studts, Proceedings of the National Academy of Sciences	2007	109
Structure−Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-<i>tert</i>-Butyl-2-<i>p</i>-tolyl-2<i>H</i>-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796) John R. Regan, Alison J. Capolino, Pier F. Cirillo, Journal of Medicinal Chemistry Drug TargetBirb 796Chemical BiologyPharmaceutical ChemistryMolecular Pharmacology	2003	105
Catalysis and Function of the p38α·MK2a Signaling Complex Susan Lukas, Rachel Kroe‐Barrett, Jessi Wildeson, Biochemistry ImmunologyMolecular BiologyComplex FormationInflammationSignaling Pathway	2004	51
Thermal Denaturation: A Method to Rank Slow Binding, High-Affinity P38α MAP Kinase Inhibitors Rachel Kroe‐Barrett, John R. Regan, Al Proto, Journal of Medicinal Chemistry	2003	45
Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling Lore Gruenbaum, Racheline Schwartz, Joseph R. Woska, Biochemical Pharmacology InflammationCytokineAutoimmune DiseaseImmune RegulationImmunology	2008	28
Determination of Kinetic Rate Constants for the Binding of Inhibitors to HIV-1 Protease and for the Association and Dissociation of Active Homodimer Christopher A. Pargellis, Maurice M. Morelock, Edward T. Graham, Biochemistry Protein AssemblyMolecular BiologyAntiviral DrugChemical BiologyActive Homodimer	1994	26

Page 1